The glucose-dependent insulinotropic polypeptide receptor: a novel target for neuroendocrine tumor imaging—first preclinical studies., PMID:24744444
Foxa1 and Foxa2 regulate α-cell differentiation, glucagon biosynthesis, and secretion., PMID:25057789
Increased GIP signaling induces adipose inflammation via a HIF-1α-dependent pathway and impairs insulin sensitivity in mice., PMID:25537494
Novel dual agonist peptide analogues derived from dogfish glucagon show promising in vitro insulin releasing actions and antihyperglycaemic activity in mice., PMID:27179756
Suppressive Effects of Glucose-Dependent Insulinotropic Polypeptide on Cardiac Hypertrophy and Fibrosis in Angiotensin II-Infused Mouse Models., PMID:27375170
Use of CRISPR/Cas9-engineered INS-1 pancreatic β cells to define the pharmacology of dual GIPR/GLP-1R agonists., PMID:27422784
Generation of a highly diverse panel of antagonistic chicken monoclonal antibodies against the GIP receptor., PMID:28055305
Inhibition of Gastric Inhibitory Polypeptide Receptor Signaling in Adipose Tissue Reduces Insulin Resistance and Hepatic Steatosis in High-Fat Diet-Fed Mice., PMID:28096257
GIP(3-30)NH2 is a potent competitive antagonist of the GIP receptor and effectively inhibits GIP-mediated insulin, glucagon, and somatostatin release., PMID:28237651
The suppressive role of miR-542-5p in NSCLC: the evidence from clinical data and in vivo validation using a chick chorioallantoic membrane model., PMID:28927388
Incretin hormones receptor signaling plays the key role in antidiabetic potential of PTY-2 against STZ-induced pancreatitis., PMID:29091882
Development and characterisation of a novel glucagon like peptide-1 receptor antibody., PMID:29119245
Characterization of 111In-labeled Glucose-Dependent Insulinotropic Polypeptide as a Radiotracer for Neuroendocrine Tumors., PMID:29440684
Gastric inhibitory polypeptide/glucose-dependent insulinotropic polypeptide signaling in adipose tissue., PMID:30248247
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism., PMID:30578168
Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake., PMID:31447324
GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice., PMID:31765668
Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive review., PMID:31809770
Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor., PMID:31905038
Chikusetsu saponin IVa protects pancreatic β cell against intermittent high glucose-induced injury by activating Wnt/β-catenin/TCF7L2 pathway., PMID:31969494
Glucagon from the phylogenetically ancient paddlefish provides a template for the design of a long-acting peptide with effective anti-diabetic and anti-obesity activities., PMID:32320703
Rapid selection of a novel GLP-1/GIP dual receptor agonist with prolonged glycemic control and weight loss in rodent animals., PMID:32598933
A Novel Anti-inflammatory Phenotype Transformed by Repetitive Low-dose Lipopolysaccharide in Primary Peritoneal Tissue-resident Macrophages., PMID:32727775
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism., PMID:33020469
Drug Occupancy Assessment at the Glucose-Dependent Insulinotropic Polypeptide Receptor by Positron Emission Tomography., PMID:33547046
Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism., PMID:33788878
Stapled, Long-Acting Xenopus GLP-1-Based Dual GLP-1/Glucagon Receptor Agonists with Potent Therapeutic Efficacy for Metabolic Disease., PMID:34240881
GLP-1/GIP/glucagon receptor triagonism gets its try in humans., PMID:34986336
GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation., PMID:35065096
GIPR gene expression in testis is mouse specific and can impact male mouse fertility., PMID:35224888
Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems., PMID:36400403
Imaging of the Glucose-Dependent Insulinotropic Polypeptide Receptor Using a Novel Radiolabeled Peptide Rationally Designed Based on Endogenous GIP and Synthetic Exendin-4 Sequences., PMID:36678558
The activation of gastric inhibitory peptide/gastric inhibitory peptide receptor axis via sonic hedgehog signaling promotes the bridging of gapped nerves in sciatic nerve injury., PMID:36971732
GIPR expression is induced by thiazolidinediones in a PPARγ-independent manner and repressed by obesogenic stimuli., PMID:37130450
Spatiotemporal regulation of GIPR signaling impacts glucose homeostasis as revealed in studies of a common GIPR variant., PMID:37925022
Introduction of a fatty acid chain modification to prolong circulatory half-life of a radioligand towards glucose-dependent insulinotropic polypeptide receptor., PMID:38241936
A Robust Platform for the Molecular Design of Potent, Protease-Stable, Long-Acting GIP Analogues., PMID:38458970
An imbalanced GLP-1R/GIPR co-agonist peptide with a site-specific N-terminal PEGylation to maximize metabolic benefits., PMID:38510128
Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite., PMID:38562891
GIP-derived GIP receptor antagonists - a review of their role in GIP receptor pharmacology., PMID:38608836
Characterization of genetic variants of GIPR reveals a contribution of β-arrestin to metabolic phenotypes., PMID:38871982
GIP attenuates neuronal oxidative stress by regulating glucose uptake in spinal cord injury of rat., PMID:38887182
Molecular dynamics-guided optimization of BGM0504 enhances dual-target agonism for combating diabetes and obesity., PMID:39030216
Incretin-responsive human pancreatic adipose tissue organoids: A functional model for fatty pancreas research., PMID:39549913
Chronic GIPR agonism results in pancreatic islet GIPR functional desensitisation., PMID:39788289
Binding Kinetics, Bias, Receptor Internalization and Effects on Insulin Secretion in vitro and in vivo of a Novel GLP-1R/GIPR Dual Agonist, HISHS-2001., PMID:39868265
The Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide Attenuates Colon Cancer Development by Regulating Glucose Metabolism., PMID:40125821
Development of a long-acting unbiased GIP receptor agonist for studies of GIP's role in bone metabolism., PMID:40132763
Targeted intervention in obesity-associated atrial fibrosis using nanoparticle-loaded fusion protein., PMID:40281309
Genome-wide interaction study with BMI identifies CYP7A1 and GIPR as genetic modulators of MASLD., PMID:40452229
For research use only. Not for human or drug use.
